Earnings Estimates Moving Higher for Certara (CERT): Time to Buy?
Certara, Inc. (CERT) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Wall Street Analysts Think Certara (CERT) Could Surge 43.28%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 43.3% in Certara (CERT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Certara, Inc. (CERT) Presents at Stephens Annual Investment Conference 2025 Transcript
Certara, Inc. ( CERT ) Stephens Annual Investment Conference 2025 November 18, 2025 2:00 PM EST Company Participants John Gallagher - SVP, Principal Accounting Officer & Chief Financial Officer Conference Call Participants Jeffrey Garro - Stephens Inc., Research Division Presentation Jeffrey Garro Stephens Inc., Research Division I think we're at the top of the hour, so we'll kick it off. A big thank you to John Gallagher, CFO of Certara, for joining us today at the Stephens Investment Conference in Nashville.
Certara, Inc. (CERT) Presents at Jefferies London Healthcare Conference 2025 Transcript
Certara, Inc. ( CERT ) Jefferies London Healthcare Conference 2025 November 18, 2025 5:30 AM EST Company Participants William Feehery - CEO & Director Conference Call Participants David Windley - Jefferies LLC, Research Division Presentation David Windley Jefferies LLC, Research Division Okay. Good morning, everybody.
Certara, Inc. (CERT) Q3 Earnings Surpass Estimates
Certara, Inc. (CERT) came out with quarterly earnings of $0.14 per share, beating the Zacks Consensus Estimate of $0.11 per share. This compares to earnings of $0.13 per share a year ago.
Analysts Estimate Certara, Inc. (CERT) to Report a Decline in Earnings: What to Look Out for
Certara (CERT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Investors Should Consider Certara Again
Certara posted strong Q1 and Q2 results, with revenue growth and non-GAAP EPS exceeding expectations, driven by biosimulation software and services. Certara's AI-enabled platforms, including the upcoming AI MIDD and CertaraIQ, are positioned as catalysts for sustainable, long-term growth in drug development. Despite a large total addressable market and cost control, Certara faces analyst downgrades, subdued market conditions, and high short interest.
Certara, Inc. (CERT) Q2 2025 Earnings Call Transcript
Certara, Inc. (NASDAQ:CERT ) Q2 2025 Earnings Conference Call August 6, 2025 5:00 PM ET Company Participants John E. Gallagher - SVP, Principal Accounting Officer & Chief Financial Officer William F.
Certara, Inc. (CERT) Q2 Earnings Miss Estimates
Certara, Inc. (CERT) came out with quarterly earnings of $0.07 per share, missing the Zacks Consensus Estimate of $0.1 per share. This compares to earnings of $0.07 per share a year ago.
Certara, Inc. (CERT) Reports Next Week: Wall Street Expects Earnings Growth
Certara (CERT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Certara (CERT) Beat Estimates Again in Its Next Earnings Report?
Certara (CERT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Certara: Ideally Positioned To Benefit From IT Innovation In Life Sciences
Certara is a leader in Model-Informed Drug Development (MIDD), offering essential software and services that reduce drug development costs and time. The company's diversified software portfolio and growing client base drive consistent revenue growth, with software revenue accelerating thanks to the Chemaxon acquisition. Certara's financials are strong, with stable cash flow, a healthy balance sheet, and a price-to-book ratio below the sector average, suggesting undervaluation.
